Related Experiment Videos
Progressive supranuclear palsy: clinical features, pathophysiology and management
1Division of Neurology, Royal University Hospital, University of Saskatchewan, Saskatchewan, Saskatoon, Canada. rajputa@sask.usask.ca
Drugs & Aging
|March 13, 2002
Summary
Progressive supranuclear palsy (PSP) is a rare brain disorder affecting movement, eye movements, and cognition. Diagnosis is challenging due to heterogeneous pathology, and treatment offers minimal sustained benefit.
Area of Science:
- Neurology
- Neuroscience
- Pathology
Background:
- Progressive supranuclear palsy (PSP) is a neurodegenerative disease of unknown cause.
- It presents as parkinsonism with early falls and abnormal eye movements.
- PSP affects men more frequently than women, with onset around 63 years.
Purpose of the Study:
- To review the clinical and neuropathological features of PSP.
- To discuss diagnostic challenges and neuroimaging's role.
- To explore the pathogenesis and therapeutic difficulties in PSP.
Main Methods:
- Review of clinical and neuropathological findings in PSP.
- Analysis of neuroimaging studies in PSP diagnosis.
- Examination of tau pathology and neurotransmitter systems in PSP.
Main Results:
- Supranuclear ophthalmoplegia is a key, though not always early, sign.
- Heterogeneous pathology affects multiple brain regions, including subthalamic nucleus and substantia nigra.
- Globose neurofibrillary tangles of phosphorylated tau are the histological hallmark.
Conclusions:
- Definitive PSP diagnosis requires clinical and neuropathological evidence.
- Pathology location correlates with clinical symptoms.
- Neurotransmitter system involvement complicates pharmacological treatment, yielding minimal sustained benefits.